ArticleFrontiers in cellular and infection microbiology2026
Machine learning prediction of pharmacist intervention benefit in tuberculosis patients using clinical parameters: a single-center retrospective study.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of long non-coding RNA HCP5 in ulcerative cutaneous tuberculosis therapy introduction.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) remains a major global health challenge, with an estimated 10 million new cases and 1.4 million deaths annually. Identifying patients who would benefit from comprehensive pharmacist intervention services is critical for optimizing pharmacist intervention benefit outcomes and resource allocation. We developed a machine learning model to predict pharmacist intervention group assignment at hospital admission using clinical parameters. Methods: We conducted a retrospective analysis of 467 TB patients from a tertiary care hospital. The prediction model was trained exclusively on clinical variables to predict pharmacist intervention group assignment (binary classification: intervention group = 1, control group = 0). To address limited sample size, we implemented data augmentation using multi-neighbor interpolation, expanding the dataset to 1,999 samples (328.1% increase). We developed an extensive feature engineering pipeline generating 122 optimized features and employed Optuna-based hyperparameter optimization (250 trials) with a multi-level ensemble architecture comprising 43 base models. Separately, we analyzed publicly available GEO datasets to provide biological interpretation and mechanistic insights, but these transcriptomic data were not used as model features. Results: The ultimate ensemble model achieved accuracy of 92.25% (95% CI: 89.1-95.4%) and AUC-ROC of 96.96% (95% CI: 94.8-99.1%) in predicting pharmacist intervention group assignment, demonstrating the substantial impact of the optimization strategies employed. Analysis of GEO datasets identified 150 significantly differentially expressed genes (FDR < 0.05) and revealed enrichment in immune response and inflammation pathways, providing supportive biological context for the clinical prediction model. Conclusions: Our study demonstrates that comprehensive machine learning optimization can achieve strong predictive performance for identifying patients who would benefit from pharmacist intervention. The clinical prediction model, trained exclusively on clinical variables, provides a robust framework for personalized TB treatment resource allocation. Supportive transcriptomic analyses provide biological context but are not used in model prediction. The model's accuracy (92.25%) and discriminative ability (AUC 96.96%) suggest potential for clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.